BioSpace News Archive

Phizzle, the leader in software used to automate data capture in biopharma applications,

Skye Bioscience, Inc. (OTCQB: SKYED) (“Skye” or the “Company”), a pharmaceutical company developing drugs targeting the endocannabinoid system, initially through modulation of the CB1 receptor

Umoja Biopharma, Inc. announced the opening of its new development and manufacturing facility, The Colorado Laboratory & Innovative Manufacturing Building in Louisville, Colo.

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) is pleased to announce that it has closed its non-brokered private placement offering

Almac Pharma Services, a member of the Almac Group providing innovative pharmaceutical development, manufacture and commercial services, has announced it is entering the final

Pleural Dynamics, a medical device company that is building solutions for chronic, recurrent fluid collections in the body, today announced that the Company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ACES™ Automatic Continuous Effusion Shunt System.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference on Wednesday, October 25 at 1:00 p.m. ET.

Centinel Spine®, LLC announced that it has completed the previously announced agreement to sell its global spine fusion product portfolio and related assets to Silony Spine.

Sight Sciences, Inc. announced they will be hosting a TearCare SAHARA Six Month RCT Results reception in San Francisco, CA on Friday, November 3, 2023 from 5:00 to 7:00 pm PT.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the successful oral delivery of a monoclonal antibody, Humira® (adalimumab), via its high-capacity capsule, the RaniPill® HC, in a preclinical study.